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Background: The oncogenic PI3K/Akt/mTOR pathway is frequently activated in HCC. Data on the mTOR inhibitor,
temsirolimus, is limited in HCC patients with concomitant chronic liver disease. The objectives of this study were:
(1) In phase I, to determine DLTs and MTD of temsirolimus in HCC patients with chronic liver disease; (2) In phase II,
to assess activity of temsirolimus in HCC, and (3) to explore potential biomarkers for response.
Methods: Major eligibility criteria included histologically confirmed advanced HCC and adequate organ function. In
Phase I part of the study, temsirolimus was given weekly in 3-weekly cycle; dose levels were 20 mg (level 1), 25 mg
(level 2) and 30 mg (level 3). The MTD was used in the subsequent phase II part; the primary endpoint was PFS and
secondary endpoints were response and OS. In addition, exploratory analysis was conducted on pre-treatment tumour
tissues to determine stathmin, pS6, pMTOR or p-AKT expressions as potential biomarkers for response. Overall survival
and PFS were calculated using the Kaplan-Meier method. Reassessment CT scans were done every 6 weeks. All adverse
events were reported using CTCAE v3.
Results: The Phase I part consisted of 19 patients, 2 of 6 patients at level 3 experienced DLT; dose level 2 was
determined to be the MTD. The phase II part consisted of 36 patients. Amongst 35 assessable patients, there were
1 PR, 20 SD and 14 PD. Overall, the median PFS was 2.83 months (95% C.I. 1.63-5.24). The median OS was 8.89 months
(95% C.I. 5.89-13.30). Grade ≥ 3 that occurred in > 10% of patients included thrombocytopenia (4) and hyponatraemia
(4). Exploratory analysis revealed that disease stabilization (defined as CR + PR + SD> 12 weeks) in tumours having high
and low pMTOR H-scores to be 70% and 29% respectively (OR 5.667, 95% CI 1.129-28.454, p = 0.035).
Conclusions: In HCC patients with chronic liver disease, the MTD of temsirolimus was 25 mg weekly in a 3-week
cycle. The targeted PFS endpoint was not reached. However, further studies to identify appropriate patient subgroup are
warranted.
Trial registration: This study has been registered in ClinicalTrials.gov (Id: NCT00321594) on 1 December 2010.
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Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer globally, and the third leading cause of can-
cer mortality both in Hong Kong and worldwide [1,2].
The outlook of patients with unresectable HCC is poor.
To date, the only systemic agent that has been shown to
provide survival benefit is sorafenib [3,4]. In parts of the
world including Hong Kong, HCC patients often present
with advanced disease stage, but the use of sorafenib has
only been approved in recent years as standard therapy.
It has been well-established that numerous genetic
abnormalities are involved in HCC; comprehensive
genomic analyses shows that components of the
phosphatidylinositol-3 kinase (PI3K)/Akt/mTOR path-
way are dysregulated in 40-50% of HCC [5-7]. On the
other hand, a meta-analysis of over 450 patients with
HCC who received liver transplant demonstrated lower
rates of recurrence and mortality for patients who received
the mTOR inhibitor (mTORI), sirolimus, for immunosup-
pression [8]. The expansion of mTORIs as a therapeutic
strategy for HCC was also strengthened by their successes
in other cancers [9-12]. In various HCC models, mTORIs
significantly reduced tumour volume and angiogenesis,
delayed tumour growth and increased survival [5,6,13-16].
Everolimus had initially been evaluated in HCC in
phase I and II studies. A US study achieved an MTD of
10 mg/day [17]; among the 25 patients enrolled, 10
achieved stable disease, one achieved partial response,
and median survival was 8.4 months. In another study,
Taiwanese patients tolerated only a daily dose of 7.5 mg,
and the median survival was 7.7 months [18]. However,
the efficacy of everolimus in HCC has not been con-
firmed by the recently reported global phase III study
(EVOLVE-1, NCT01035229) [19].
Temsirolimus is a prodrug of sirolimus; it is adminis-
tered intravenously and has a long half-life of 73 hours.
To date, there has been limited clinical data on the use
of temsirolimus in HCC patients who often suffer from
chronic liver disease. We conducted a phase I/II study
of temsirolimus (Torisel®) in patients with unresectable
HCC, majority of whom had concomitant hepatitis B
virus-related chronic liver disease. The objectives in the
phase I study were to determine dose limiting toxicity
(DLT) and maximum tolerated dose (MTD). Once the
MTD was determined, the phase II portion of the study
was conducted to determine the activity of temsirolimus.
Although promising results have been shown with tem-
sirolimus in a number of malignancies, there has been
very limited data on potential biomarkers that could en-
able appropriate selection of tumours which are likely to
undergo a favorable clinical response. Further, the failure
to demonstrate efficacy of everolimus in the EVOLVE
study has highlighted the potential importance of appro-
priate patient selection. Thus, in the current study, anexploratory analysis was also conducted to determine if
the expression of stathmin, pS6, pMTOR and p-AKT
might be predictive for response to temsirolimus in HCC.
Methods
Eligibility criteria included: Histologically/cytologically
confirmed unresectable HCC; ECOG ≤2; measurable
disease; life expectancy > 12 weeks; absolute neutrophil
count ≥ 1.5 × 109/L, platelets ≥ 80 × 109/l, serum creatin-
ine ≤ 150 μmol/L, total bilirubin ≤ 30 umol/l, albumin ≥
28 g/l, alanine transaminases ≤ 5.0 × UNL (institutional
upper normal limit), alkaline phosphatase ≤ 6 × UNL,
prothrombin time ≤ 4 sec of ULN, and absence of
clinical ascites.
The main exclusion criteria were Child’s B or C cirrho-
sis, use of other systemic treatments within 3 weeks
prior to study entry; prior use of mTORI; significant car-
diovascular disease; severe impairment of lung function;
poorly controlled diabetes mellitus; and ≥ grade 2 pre-
existing neuropathy.
Written consent was sought from individual patient to
participate in the study and for the exploratory analysis
that involved the use of tissue obtained for diagnostic
purpose. This study was approved by the Clinical Re-
search Ethics Committee of the Joint NTEC-Review
Board of the Chinese University of Hong Kong, and has
been registered in ClinicalTrials.gov (Id: NCT00321594).
Pretreatment evaluation
All patients underwent complete medical history and
physical examination, blood profiles including complete
blood counts, renal and liver functions, fasting glucose
and lipids, clotting profiles, alpha-fetoprotein (AFP), and
hepatitis B surface antigen (HBsAg), hepatitis C antibody
(anti-HCV), chest x-ray and CT scan of abdomen and/or
other disease sites were performed.
Treatment plan
Temsirolimus was added to 250 mL of 0.9% sodium
chloride and administered intravenously over 30 minutes
weekly, every 3 weeks. All patients received premedica-
tion with diphenhydramine 25 mg or 50 mg IV bolus
dose 30 minutes prior to temsirolimus. Standard anti-
emetics included at least a 5-HT3 antagonist. Patients
who were HBsAg seropositive were also given lamivu-
dine prior to study treatment.
Phase I study
For the phase 1 study, there were 5 dose levels of temsiro-
limus: 10 (level −2), 15 (level −1), 20 (level 1), 25 (level 2)
and 30 mg/week (level 3). Level 1 was the starting dose
level.
DLT was defined during cycle 1 as: any grade 4
hematological toxicity; grade ≥3 non-hematological
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or diarrhoea that did not respond to therapy; and treat-
ment delay > 2 weeks.
The conventional 3 + 3 design was employed. Dose
escalation was based on the modified Fibonacci method
[20]. The MTD was defined as the dose below which ≥ 2
of 3 or ≥ 2 of 6 patients experiencing DLT. A total of 10
patients were entered into the MTD to further define
toxicity.
Treatment delay and modification
For each cycle, treatment was delayed if the ANC
was <1.5 × 109/L or platelet count was < 75 × 109/ml
on the scheduled day of drug administration. Patients
who experienced grade 3 non-haematological toxicity,
thrombocytopenia or febrile neutropenia, as well as
grade 4 neutropenia continued to receive temsirolimus
at the next lower dose level upon resolution of all
toxicities to grade 1. For an individual, there could be a
limit of two dose de-escalations for serious toxicity.
The drug was discontinued for toxicities of the fol-
lowing nature: grade 4 non-hematological toxicities,
thrombocytopenia/febrile neutropenia/recurrent grade
4 neutropenia despite dose reduction, as well as any
haematological or non-haematological toxicity requir-
ing interruption for ≥ 3 weeks.
Treatment was continued provided that toxicities were
tolerable or until one of the following criteria applied:
disease progression; intercurrent illness that prevented
further treatment administration; unacceptable adverse
events; patient’s decision; or investigator’s judgment.
Phase II study
Upon determination of MTD, patients were enrolled
into the phase II part of the trial at MTD; the 10 pa-
tients at the MTD in phase I were included in the phase
II analysis.
Definitions of response and toxicity
Tumour response assessment with CT every two cycles
was assessed according to the Response Evaluation
Criteria in Solid Tumors (RECIST) Committee [21].
Toxicity was graded according to Common Toxicity
Criteria of the National Cancer Institute (NCI-CTC v3).
Methodology for stathmin, pS6, pMTOR and p-AKT
immunohistochemistry
Thirty-four patients had pre-treatment tissues available
for this analysis. For immunohistochemistry, 5-μm tissue
sections were prepared from each block. Tissue sections
were deparaffinized, rehydrated and rinsed in distilled
water. Antigen retrieval was done by using pressure
cooker with 10 nM citrate buffer (pH 6.0) for 25 minutes.
The endogenous peroxidase activity was then blocked byincubating the slides in 3% hydrogen peroxide in metha-
nol for 10 min. The primary antibodies used in this
study were STMN1 (1:50), pS6 (Ser235/236, 1:100),
pMTOR (Ser2448, 1:50) and p-AKT (Ser473, clone
D9E, 1:25) from Cell Signaling Technology (Danvers
MA). The primary antibodies were incubated at 4°C
overnight and chromogen development was performed
using the DAKO EnVision System (Glostrup, Denmark)
except for p-AKT, which was detected using the OptiView
DAB IHC Detection Kit (Ventana Medical Systems).
An intensity score of 0 to 3 was assigned for the inten-
sity of tumour cells (0, none; 1, weak; 2, intermediate; 3,
strong). A proportional score was given by the estimated
proportion of positive tumour cells in percentage. To
assess the average degree of staining within a tumour,
multiple regions were analyzed, and at least 100 tumour
cells were assessed. The cytoplasmic expression was
assessed by H-score system [22]. The formula for the
H-score is: Histoscore = ∑(I × Pi), where I = intensity of
staining and Pi = percentage of stained tumour cells,
producing a cytoplasmic score ranging from 0 to 300.
The scoring was independently assessed by two assessors
(AWHC and JHMT) who were not aware of the clinical
outcomes.
Statistical methods
For the Phase I portion, the estimated patient number
would be 14–19. For the phase II portion, the primary
endpoint was progression free survival (PFS). The sec-
ondary endpoints were response according to RECIST,
overall survival (OS) and toxicity. The PFS was assessed
from day 1 of treatment cycle 1 to the date when object-
ive disease progression was observed. OS was calculated
from day 1 of treatment cycle 1 to the date of death.
Death was regarded as a progression event in those sub-
jects who died before disease progression. Subjects with-
out documented objective progression at the time of the
final analysis were censored at the date of their last
tumour assessment. Survival curves were constructed
using the Kaplan–Meier method.
The planned accrual for phase II was 30 assessable
patients. Patients are considered assessable if they have
completed ≥ 1 cycle of treatment or are removed from
study due to disease progression. If the PFS at 3 months
is ≤ 0.5, the regimen would be considered inactive. If the
PFS at 3 months is ≥ 0.66, this regimen would be consid-
ered worthy of further investigation. If ≥ 18 of 30 assess-
able patients are observed to be progression-free by
3 months, the study would have 80% power and 0.18
significance level. An additional 6 patients (i.e. 20%) would
be accrued to account for ineligibility, cancellation, major
treatment violation, or other reasons. Therefore, the
maximum accrual would be 36 patients (including the
10 patients from phase I at MTD). In order to observe
Table 2 Baseline patient characteristics in phase II study
Characteristic No. of patients %











Hepatitis B 29 80.5
Hepatitis C 1 2.8
Non-B non-C 6 16.7




BCLC Stage B 28
BCLC stage C 8
Macroscopic vascular invasion 24 66.7
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followed up for at least 3 months.
Exploratory analysis on cytoplasmic expression of the
biomarkers was viewed as hypothesis generating. The
optimal cutoff for stathmin, pS6, pMTOR and p-AKT
was determined by the receiver operating characteristic
(ROC) curve distribution analysis [23,24]. Out of a total
H-score of 300, the threshold for differentiating between
positive and negative immunostaining were set at H-
scores of 15, 120, 20 and 5 respectively; tumours were
categorized as ‘low H-score’ and ‘high H-score’ depend-
ing on whether the individual score were ‘lower than or
equal to’ or ‘higher than’ the respective thresholds.
Response rates in terms of disease stabilization (defined
as complete response [CR] + partial response [PR] +
stable disease [SD] ≥ 12 weeks) and AFP drop in asso-
ciation with H-scores of stathmin, pS6, pMTOR and
p-AKT cytoplasmic were compared using Fisher’s exact
and proportional hazard model where applicable. Re-
sponse assessment based on AFP was conducted for
patients whose baseline AFP > 20 ng/ml and who had
2 cycles of study treatment. The drop in AFP based on
baseline AFP was compared with the lowest level of
AFP detected after 2 cycles of study treatment, and
AFP response was defined as a > 20% decrease in AFP
value [25].Table 1 Summary of dose level and dose-limiting
toxicities in phase 1












012 3 Treatment delay for > 2 weeks








Extrahepatic disease 21 58.3
Prior therapy for HCC of any forms 29 80.6
Blood parameters (median, range):
Total bilirubin 16 (5–34) umol/l
Albumin 39. (32–48) g/l
Alanine transaminase 40 (18–140) iu/l
Alkaline phosphatase 108 (52–434) iu/l
AFP 82 (1–118712) ug/l
INR 1.06 (0.89-1.26)
Creatinine 82 (44–136) umol/l
Glucose 5.4 (4.0-8.5) mmol/l
Triglyceride 0.9 (0.5-2.0) mmol/l
LDL cholesterol 2.65 (1.6-7.3) mmol/l
HDL cholesterol 1.15 (0.7-2.5) mmol/l
Total cholesterol 4.45 (3.0-8.9) mmol/l
Prior systemic therapy
1 line 11 30.5
2 lines 1 2.8
3 lines 1 2.8
Prior local +/− regional therapy
Surgery 23 63.9
*Local ablation 4 11.0
Transarterial therapy 20 55.5
*2 had radiofrequency ablation and 2 had percutaneous ethanol injection.
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From November 2009 to December 2011, a total of 45
patients were consented and entered.
Phase I study
Patient characteristics and study drug dosing
Nineteen patients were entered, 3 in level 1, 10 in level 2
and 6 in level 3 (Table 1). The median age was 56.0 years
(range 36–77). Fifteen (79%) were male, 14 (78%) had
ECOG 0. Fifteen (79%) had chronic HBV and 1 was
hepatitis C seropositive.
Two out of 6 patients developed DLTs at level 3 (dose
being 30 mg/week), including 1 who developed grade 3
syncope and 1 who had treatment delay for > 2 weeks
due to prolonged neutropenia. Temsirolimus dose of
25 mg/week was declared as the MTD and the recom-
mended phase II dose; at the MTD, temsirolimus was
well tolerated with no DLTs. The 10 patients enrolled





Figure 1 (a) Progression-free survival; (b) Overall survival of patients in thePhase II study
Patient characteristics
The following analyses pertain to the 36 patients who
were being enrolled into the phase II study.
Patient characteristics are shown in Table 2. Of
note, 27 patients had BCLC stage C [26], 9 had
BCLC stage B (including 8 who failed multiple lines
of loco-regional therapies and 1 who had extensive
intrahepatic disease); 24 (66.7%) had vascular involve-
ment and 21 (58.3%) had extrahepatic metastases.
Twenty-nine patients (80.5%) had received prior treat-
ment for HCC; 13 (36.1%) had received ≥1 line of
prior systemic therapies; 10 of the latter had received
anti-vascular endothelial growth factor tyrosine kinase
inhibitors (anti-VEGF TKIs). The median number of
cycles was 3.5 (range: 1–16). Twelve (34%) patients
underwent at least 6 cycles of temsirolimus. The
follow-up data was frozen on 31 December 2013. The
median follow-up was 8.89 months (95% C.I. 5.89-
13.30). At the time of data cutoff, all patients hadedian PFS 2.83 months (95% C.I. 1.63-5.24) 
3-month PFS 0.47 (95% C.I. 0.31-0.64)
edian OS 8.89 months (95% C.I. 5.89-13.30)
phase II study.
Table 3 Haematological and non-haematological toxicities
according to the NCI CTC (version 3.0) (n = 35)
Worst grade (number
of patients)
Toxicities 1-2 3 4
Mucositis- oral 26 1 0
Rash 20 0 0
Fatigue 17 1 0
Cough 15 1 0
Fever 14 0 0
Anorexia 13 0 0
Pulmonary-Other 13 0 0
Insomnia 12 0 0
Pain- head 12 0 0
Pain- abdomen 10 1 0
Haemorrhage, nose 10 0 0
Oedema- limb 10 0 0
Pruritus 10 0 0
Gastrointestinal-Other 9 0 0
Diarrhoea 8 3 0
Dysphagia 8 1 0
Nausea 8 0 0
Pain- others 8 0 0
Platelets 7 4 0
Dyspnoea 7 1 0
Constipation 7 0 0
Distension 7 0 0
Dry mouth 7 0 0
Haemorrhage, other 6 0 0
Rigors/chills 6 0 0
Vomiting 6 0 0
Hyperglycaemia 5 1 0
Dizziness 5 0 0
Dry skin 5 0 0
Musculoskeletal-Other 5 0 0
Pain- muscle 5 0 0
Taste alteration 5 0 0
Hypokalaemia 4 1 1
Hemorrhoids 4 1 0
Hyponatraemia 0 4 0
Ascites 4 0 0
Infection- others with normal
neutrophil counts
4 0 0
Alanine transaminase 3 2 0
Hyperbilirubinaemia 1 2 1
Infection- upper airway with normal
neutrophil counts
1 3 0
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due to liver failure and another due to pneumonia.
Response and survival
One patient was not assessable for response as he went
abroad after receiving cycle 1 week 1 of temsirolimus.
Amongst the 35 assessable patients, the best responses
were: 1 PR (3%), 20 SD (57%) and 14 progressive disease
[PD] (40.0%); 40% had disease stabilization.
Overall, the median PFS was 2.83 months (95% C.I.
1.63-5.24); the 3-month PFS was 0.47 (95% C.I. 0.31-
0.64) (Figure 1a). The median OS was 8.89 months
(95% C.I. 5.89-13.30) (Figure 1b).
Unplanned exploratory analyses revealed that patients
who received prior anti-VEGF TKIs had similar PFS and
OS compared with those who did not. In addition, treat-
ment outcome was not associated with viral etiologies
(data not shown).
Toxicity
In the phase II portion study, toxicity was assessable in
the 35 patients (Table 3). The most common adverse
events that occurred in > 30% of patients included oral
mucositis, rash, fatigue, cough, non-neutropenic fever,
anorexia, insomnia, diarrhea, thrombocytopenia, and pain
in abdomen and head. Grade ≥ 3 events that occurred
in > 10% included hyponatraemia and thrombocytopenia.
Of note, hyperglycaemia occurred in 6 patients (17%;
4 grade 1–2 and 1 grade 3), while 1 patient developed
grade 2 hypercholesterolaemia; all could be managed
with standard medical therapies. Two patients developed
interstitial pneumonitis, which resolved with corticoster-
oid and discontinuation of temsirolimus.
Exploratory analysis
Of the 35 assessable patients, 34 had pre-treatment
tumour tissues available for this analysis, there were 14
patients who achieved disease stabilization.
The H-scores for stathmin, pS6, pMTOR and pAKT
of individual patient’s tumour are listed in Table 4. The
immunohistochemical findings with respect to H-scores
for stathmin, pS6, pMTOR and pAKT are illustrated in
Figure 2. Analysis of the H-scores in association with
disease stabilization and AFP drop are detailed in Table 5.
Only pMTOR was found to be associated with disease
stabilization, 7 of the 10 patients (70%) who had high
H-scores (> 20/300) achieved disease stabilization, in
contrast to 7 out of 24 (29%) who had low H-scores
(p = 0.028). The odds ratio (OR) for disease stabilization
for high vs. low pMTOR H-scores is 5.667 (95% C.I.
1.129-28.454, p = 0.035).
Of the 36 patients, 22 were eligible for AFP response;
there were 8 AFP responders and 14 non-responders.
Correlation study of AFP response with H-scores for
Table 4 Virological status, H-scores for stathmin, pS6, pMTOR and pAKT and clinical outcome in terms of having
achieved disease stabilization of individual patient’s tumour
Patient no. HBV/HCV/ Non-B non-C Stathmin pS6 pMTOR pAkt Disease stabilization
PW004 HBV High Low Low High No
PW005 HBV High High Low High No
PW014 HBV Low High Low Low No
PW018 HBV High Low Low Low No
PW019 HBV Low High Low Low No
PW020 Non-B, Non C Low High Low High No
PW023 HCV High Low High Low No
PW024 HBV High High Low High No
PW025 HBV High Low Low High No
PW028 HBV High Low Low High No
PW029 Non-B, Non C Low Low Low Low No
PW030 HBV High Low Low Low No
PW031 HBV High Low Low Low No
PW032 HBV High High Low Low No
PW034 HBV High High Low High No
PW035 Non-B, Non C Low Low High Low No
PW036 HBV Low High High Low No
PW039 HBV High Low Low Low No
PW040 Non-B, Non C High High Low Low No
PW042 HBV High Low Low Low No
PW015 HBV High High High Low Yes
PW016 HBV High High Low Low Yes
PW017 Non-B, Non C Low Low Low Low Yes
PW021 HBV Low Low High Low Yes
PW022 Non-B, Non C Low Low High Low Yes
PW026 HBV Low Low Low Low Yes
PW027 HBV High High Low High Yes
PW033 HBV High Low High High Yes
PW037 HBV Low High High Low Yes
PW038 HBV High High Low Low Yes
PW043 HBV High High High High Yes
PW044 HBV Low Low Low Low Yes
PW045 HBV Low High High High Yes
PW046 HBV High High Low Low Yes
HBV- hepatitis B virus, HCV- hepatitis C virus, Non-B non-C- negative for hepatitis B or C.
Disease stabilization rate = (CR + PR + SD) >12 weeks.
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Of interest, AFP response for high vs. low pMTOR scores
occurred in 67% and 20% respectively (p = 0.085).
Discussion
The present study confirmed the MTD for temsirolimus
in patients with chronic liver disease and advanced HCC
to be 25 mg weekly, which is the approved dose for
metastatic renal cell carcinoma [9,10]. Common adversereactions of temsirolimus noted in this study were con-
sistent with the reported toxicity profile of this agent,
which included skin and mucosal toxicities, constitu-
tional symptoms (fatigue, anorexia, insomnia), myelo-
suppression, metabolic disturbances (disturbances in
glucose and lipids controls) and the uncommon but
well-known occurrence of interstitial pneumonitis.
In an unselected population of advanced HCC patients,
the current study reveals that the use of temsirolimus
A. high stathmin H-score (2/300). B. low stathmin H-score (210/300).
C. high pS6 H-score (0/300). D. low pS6 H-score (270/300). 
G. high p-AKT H-score (5/300).
E. high pMTOR H-score (3/300). F. low pMTOR H-score (105/300). 
H. low p-AKT H-score (240/300).
Figure 2 Immunohistochemical staining of pretreatment tumour tissues. A. high stathmin H-score (2/300). B. low stathmin H-score (210/300).
C. high pS6 H-score (0/300). D. low pS6 H-score (270/300). E. high pMTOR H-score (3/300). F. low pMTOR H-score (105/300). G. high p-AKT
H-score (5/300). H. low p-AKT H-score (240/300).
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pre-specified limit considered to be efficacious. The
present finding is in line with that of the EVOLVE study,
in which everolimus has failed to achieve the primary end-
point in improving OS in an unselected HCC patient
population who had progressed on sorafenib [19]. The dis-
couraging result sheds light to the potential importance of
suitable patient selection.There has been limited ability to identify biomarkers for
appropriate utilization of mTORIs. In the phase I study of
everolimus, 11 HCC patients had pre-treatment tumour
tissues available for assessment, one patient achieved PR
and the tumour showed moderate to high levels of p-AKT,
p-MTOR and pS6 [17]. The key effector in the PI3K/Akt/
mTOR pathway is mTOR, which has a critical role
in regulating cell proliferation, survival and angiogenesis
Table 5 Exploratory analysis on H-scores for stathmin, pS6, pMTOR and pAKT
Stathmin
H-scores Range: 0-300/300; Optimal Cut-off*: 15/300
H-scores: High vs. Low High H-scores (>15/300) Low H-scores (≤15/300)
Disease stabilization rate** 7/21 (33%) 7/13 (46%) p = 0.238
OR for disease stabilization** 0.429 (95% CI 0.104-1.770) p = 0.242
AFP response*** 2/6 (33%) 6/16 (38%) p = 0.376
pS6
H-scores Range: 0-300/300; Optimal Cut-off*:120/300
H-scores: High vs. Low High H-scores (>120/300) Low H-scores (≤120/300)
Disease stabilization rate** 8/17 (47%) 6/17 (35%) p = 0.489
OR for disease stabilization** 1.630 (95% CI 0.411-6.459) p = 0.487
AFP response*** 4/11 (36%) 4/11 (36%) p = 0.341
pMTOR
H-scores Range: 0-180/300; Optimal Cut-off*: 20/300
H-scores: High vs. Low High H-scores (>20/300) Low H-scores (≤20/300)
Disease stabilization rate** 7/10 (70%) 7/24 (29%) p = 0.028
OR for disease stabilization** 5.667 (95% CI 1.129-28.454) p = 0.035
AFP response 4/16 (25%) 4/6 (67%) p = 0.085
pAKT
H-scores Range: 0-240/300; Optimal Cut-off*: 5/300
H-scores: High vs. Low High H-scores (>5/300) Low H-scores (≤5/300)
Disease stabilization rate** 4/11 (36%) 10/23 (43%) p = 0.693
OR for disease stabilization** 0.743 (95% CI 0.169-3.262) p = 0.694
AFP response*** 7/16 (44%) 1/6 (17%) p = 0.215
*H-scores Optimal Cut-off based on ROC.
**Disease stabilization rate (CR + PR + SD) ≥12 weeks, number of patients available for analysis = 34; disease stabilization in association with H-scores were
compared using Fisher’s exact and proportional hazard model.
***AFP response, number of patients available for analysis = 22; AFP drop in association with H-scores were compared using Fisher’s exact.
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marker for effective mTOR inhibition in breast cancer
[29,30], unfortunately, a recent report on endometrial
cancer did not support this [31]. Further, the reported
rate of mutations in the PIK3CA gene has been incon-
sistent in HCC varying from 0-35% [32,33]. Activated
PI3K propels two downstream effectors: mTOR com-
plex 2 (mTORC2) and Akt. Akt activates mTORC1
which in turn activates downstream effector, the serine/
threonine kinase, S6K1. S6K1 participates in numerous
cellular processes central to promoting cell prolifera-
tion, cell growth and cell cycle progression [34,35].
Phosphorylated mTOR and p-S6K is elevated in ap-
proximately 40% of HCC [6,27,36]. It has been observed
that loss of PTEN, the negative regulator of PI3K, re-
sults in robust activation of this pathway [37,38], and
stathmin, encoded by the signature gene STMN1, has
been suggested to be a more accurate immunohisto-
chemical marker of the PTEN signature [39]. These data
have prompted us to explore the possibility of stathmin,pAKT, pMTOR and pS6 as potential biomarkers for
response.
The present exploratory analyses show pMTOR to be
the only marker associated with disease stabilization
effect of temsirolimus. Although some studies suggested
that pMTOR overexpression may have prognostic im-
pact independent of temsirolimus, studies in different
tumour types have reported conflicting results [40-42].
Specifically, a study in HCC patients undergoing ortho-
topic liver transplantation reported mTOR pathway
to be active in 40% of the patients, but none of the
biomarkers [PTEN, p-AKT, p-mTOR, p-p70S6K and p-
4EBP-1] were associated with survival [43]. In this
current study, assessment of pMTOR in relation to pres-
ence of vascular invasion and tumour grading was
attempted; unfortunately, 22 of the 34 tumour analyzed
were biopsy samples which limits detail pathological
assessment.
On the other hand, the effect of rapalogs on Akt may
vary with drug dose, with lower doses increasing Akt
Yeo et al. BMC Cancer  (2015) 15:395 Page 10 of 11activation while higher doses diminishing Akt activity
[44,45]. In addition, the effect on Akt also varies with
cell type [46]. Thus, determining the clinical effects of
different dosages of mTORIs could be an important
tactic to overcoming such limitation.
Further, combining mTORIs with other systemic
agents could improve clinical efficacy. The combination
of everolimus and sorafenib has been reported to syner-
gistically inhibit proliferation and tumor growth in
HCC cell lines and xenografts [14]. A phase I study of
this combination in advanced HCC patients yielded
an encouraging 8% PR and 60% SD [47]. In addition,
studies have shown that the activation of Akt markedly
increases the resistance against microtubule-directed
cytotoxic agents while mTORIs could inhibit this
resistance [48,49].
Conclusions
In summary, this study demonstrates that temsirolimus
enables disease stabilization with tolerable toxicity pro-
file among HCC patients. Although the efficacy data has
not reached the pre-specified PFS endpoint, patients
with tumours having a high pMTOR score were more
likely to achieve disease stabilization. In this respect, a
recent study among bladder cancer patients have re-
ported that everolimus was more effective in patients
with a somatic mutation in the TSC1 complex [50].
Therefore, the role pMTOR and TSC1 mutation as
potential biomarkers for efficacy of mTOR inhibition
should further be explored to enable better selection of
appropriate patient population. However, further im-
provement in clinical efficacy for HCC will likely require
combining mTORIs with other novel compounds.
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